₹ 1.0 Cr
Volume Transacted
(Jan 14, 2025)
1.5 K
Stocks Traded
(Jan 14, 2025)
Last Updated on: Jan 14, 2025
Astrazeneca Pharma India Ltd
NSE: ASTRAZEN
EPS
₹ 51.49
Last updated on: Jan 14, 2025
Open Demat Account
Enter your mobile no. to continue
+91
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
Historical Earning per Share of Astrazeneca Pharma India Ltd
EPS, or Earnings Per Share, is a financial metric that represents the portion of a company's profit allocated to each outstanding share of common stock. It indicates a company's profitability and is calculated by dividing net income by the number of outstanding shares.
No data available
* All values are in ₹
Market Cap
₹ 17,575 Cr
EPS
₹ 51.5
P/E Ratio (TTM) *
136.5
P/B Ratio (TTM) *
25.9
Day’s High *
7473.95
Day’s Low
₹ 6868.55
DTE *
0.0
ROE *
18.9
52 Week High
₹ 8139.85
52 Week Low
₹ 4050.15
ROCE *
23.9
* All values are consolidated
Last Updated time: 14 Jan 15:30 PM
* All values are consolidated
Last Updated time: 14 Jan 15:30 PM
The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.
1M
1Y
3Y
5Y
Date | Price (₹) | Day Open (₹) | Day High (₹) | Day Low (₹) |
---|
14 Jan 2025 | 7030.35 | 7473.95 | 7473.95 | 6868.55 |
13 Jan 2025 | 7043.7 | 6809.8 | 7199.9 | 6769.55 |
10 Jan 2025 | 6912.5 | 7040 | 7040 | 6854.95 |
09 Jan 2025 | 7076 | 6946.9 | 7518.3 | 6946.9 |
08 Jan 2025 | 6892.55 | 7050 | 7069.9 | 6851.2 |
07 Jan 2025 | 7092.85 | 7275.45 | 7384.4 | 7011 |
06 Jan 2025 | 7251.75 | 7173 | 7392.75 | 6910.6 |
03 Jan 2025 | 7113.75 | 7173.95 | 7194.9 | 7009.9 |
02 Jan 2025 | 7137.75 | 7220 | 7220 | 7112 |
01 Jan 2025 | 7206.4 | 7007.05 | 7380.55 | 7007.05 |
Date | Price (₹) |
---|---|
14 Jan 2025 | 7030.35 |
13 Jan 2025 | 7043.7 |
10 Jan 2025 | 6912.5 |
09 Jan 2025 | 7076 |
08 Jan 2025 | 6892.55 |
07 Jan 2025 | 7092.85 |
06 Jan 2025 | 7251.75 |
03 Jan 2025 | 7113.75 |
02 Jan 2025 | 7137.75 |
01 Jan 2025 | 7206.4 |
Revenue
Profitability
Affordability
Liquidity
Dividend
Market Value
₹ 17,576
Asset Value
₹ 955
17.4 X
Value addition
* All values are in Rupees
Company Name | EPS | Market Cap (INR Cr.) |
---|---|---|
Astrazeneca Pharma India Ltd | 51 | 17,575 |
Sun Pharmaceuticals Industries Ltd | 46 | 4,24,382 |
Divis Laboratories Ltd | 69 | 1,59,224 |
Cipla Ltd | 57 | 1,16,943 |
Dr Reddys Laboratories Ltd | 63 | 1,11,588 |
Mankind Pharma Ltd | 51 | 1,10,215 |
Historical Market Cap of Astrazeneca Pharma India Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
No data available
* All values are in ₹ crore
Historical Revenue of Astrazeneca Pharma India Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
No data available
* All values are in ₹ crore
Historical EBITDA of Astrazeneca Pharma India Ltd
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
No data available
* All values are in ₹ crore
Historical Net Profit of Astrazeneca Pharma India Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
No data available
* All values are in ₹ crore
No data available
Volumes spurt at Astrazeneca Pharma India Ltd counter
Happiest Minds Technologies Ltd, Campus Activewear Ltd, Cera Sanitaryware Ltd, ITI Ltd are...
30 Dec 2024 14:30
AstraZeneca gets CDSCO nod to import cancer drug, Lynparza
This approval establishes the use of Olaparib in combination with Durvalumab as a maintena...
26 Nov 2024 14:49
AstraZeneca Pharma gains on plan to launch COPD drug
Earlier, on 2 December 2023, the pharma company intimated about the receipt of import and ...
19 Nov 2024 12:11
AstraZeneca slumps as Q2 PAT slides 27% YoY to Rs 38 cr
Revenue from operations jumped 31.16% year on year (YoY) to Rs 408 crore in the quarter en...
14 Nov 2024 12:34
Astrazeneca Pharma India to announce Quarterly Result
Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 1...
25 Oct 2024 16:11
Astrazenenca Pharma gets CDSCO nod to import Durvalumab solutions
Durvalumab (IMFINZI) in combination with chemotherapy as neoadjuvant treatment, followed b...
24 Sep 2024 08:54
Unlimited trading starting at just Rs. 249*